Apceth, Indivumed to develop tissue-based biomarker strategy
The collaboration will analyse the response of a targeted therapy in different cancer types and stratify patients to provide a more individualized cancer treatment with Apceth’s cell and
Harbour BioMed and Kelun-Biotech have received approval from China’s National Medical Products Administration (NMPA) for their investigational new drug (IND) application for the HBM7575/SKB575 bispecific antibody intended to treat asthma.
The study reveals that C-peptide production can persist for decades after disease onset and remains functionally responsive. This suggests that patients with advanced disease, whose ß-cell function was